FindTrial
Sign In

Management of Chemo Induced Myelosuppression with integrated Rasayana Therapy

Assessment of treatment outcome with integrating Rasayana therapy along with Chemotherapy into the continuum of care of chemotherapy induced myelosuppression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/028128
Enrollment
30
Registered
2020-09-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Personalised Rasayana Therapy including Tejoj Rasayan 350 mg -2 capsules orally with honey daily for 6 months during chemotherapy: Tejoj Rasayan - It is best herbomineral preparation

Sponsors

Rasayu Cancer Clinic Pune
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Biopsy confirmed cases of any carcinoma at any stage 2 Willing to take chemotherapy along with Rasayana therapy

Exclusion criteria

Exclusion criteria: 1 Patient taking radiotherapy 2 Patients taking any other treatment besides chemotherapy

Design outcomes

Primary

MeasureTime frame
To assess heamatological toxicities -anemia, Neutropenia and thrombocytopenia etc using heamogram assessmentTimepoint: at baseline ( 1 day before chemotherapy)—

Secondary

MeasureTime frame
1.To assess chemotherapy symptom assessment scale score 2. To assess adverse drug reactions using CTCAE v 5 and 3.To asess quality of life and Physical performance status by using Fact G and ECOG measuring tool Timepoint: pre ( at 1 day before) and post ( at 1 day before of next schedule of each chemotherapy cycle)—

Countries

India

Contacts

Public ContactDr Yogesh Bendale

Rasayu Cancer Clinic

dr.bendale@gmail.com02024537149

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026